• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Nationwide Rollout of Elecsys pTau-217 Alzheimer’s Blood Test Could Be A Game Changer For Labcorp (LH)

    Simply Wall St·08/26/2026 05:22:03
    语音播报
    • In August 2026, Labcorp announced it would offer the FDA-cleared Elecsys pTau-217 blood test, the first single-biomarker assay able to both rule in and rule out amyloid pathology associated with Alzheimer’s disease in people 55 and older with cognitive concerns, across primary and specialty care settings.
    • This move broadens Labcorp’s Alzheimer’s testing portfolio and highlights how standardized, minimally invasive blood-based diagnostics could reshape how clinicians assess potential amyloid pathology in everyday practice.
    • We’ll examine how Labcorp’s nationwide rollout of the Elecsys pTau-217 Alzheimer’s test may influence its investment narrative and growth drivers.

    Uncover the next big thing with 22 elite penny stocks that balance risk and reward.

    Labcorp Holdings Investment Narrative Recap

    To own Labcorp, you need to believe that broad, high quality diagnostics and specialty testing can compound value even as reimbursement and regulatory pressures persist. The nationwide rollout of the Elecsys pTau 217 Alzheimer’s blood test reinforces the core catalyst of new test adoption, but it does not materially change the near term risk that pricing and policy changes, including PAMA, could weigh on margins and growth.

    The August 18 alliance with the National Association of Community Health Centers sits neatly alongside the pTau 217 launch, because it underlines Labcorp’s push deeper into primary care, where standardized, minimally invasive tests like pTau 217 and pTau 181 may help drive volume growth if clinicians and payers embrace them.

    Yet, against this backdrop of innovation and partnerships, investors should also be aware that reimbursement pressure, including potential PAMA impacts, could still...

    Read the full narrative on Labcorp Holdings (it's free!)

    Labcorp Holdings' narrative projects $16.6 billion revenue and $1.4 billion earnings by 2029. This requires 5.0% yearly revenue growth and an earnings increase of about $0.4 billion from $1.0 billion.

    Uncover how Labcorp Holdings' forecasts yield a $337.75 fair value, in line with its current price.

    Exploring Other Perspectives

    LH 1-Year Stock Price Chart
    LH 1-Year Stock Price Chart

    Three members of the Simply Wall St Community currently estimate Labcorp’s fair value between US$260 and US$337.75, underlining how far opinions can diverge. When you weigh those views against the catalyst of expanding Alzheimer’s and neurology testing, it becomes even more important to compare different assumptions about how new assays might influence future revenue and profitability.

    Explore 3 other fair value estimates on Labcorp Holdings - why the stock might be worth as much as $337.75!

    Reach Your Own Conclusion

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    No Opportunity In Labcorp Holdings?

    Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.